Natco Pharma shares crash 18% after weak Q3 results, marking a 25% drop in five days. Profit declined by 37.7% to ₹132.4 crore due to lower exports.
Natco Pharma shares experienced a significant drop, crashing 18% following the announcement of weak Q3 results. This decline extends a downward trend, with the stock falling 25% in the past five days.
On Thursday, February 13, Natco Pharma shares continued to trade with losses, marking the fifth consecutive day of decline. The company reported a net profit of ₹132.4 crore, a substantial decrease of 37.7% compared to the previous year’s ₹212.7 crore.
NATCO Pharma Share Price Performance
The shares of NATCO Pharma Ltd, a component of the BSE 500, plummeted 20% on Thursday, February 13, 2025. The stock opened with a gap down, losing 18.96%. The session began at Rs 986, a significant drop from the previous close of Rs 1216.65 on the BSE. The price further declined to an intra-day low of Rs 975, representing a 19.86% decrease from the last trading price. At the NSE, the stock fell 19.99% to Rs 975.05.
This sharp decline followed the company’s report of a 37.75% decline in consolidated net profit for the December quarter.
NATCO Pharma Share Price History
Over the past year, the stock has provided a positive return of 15.86% to its investors. In a two-year period, the return was 86.01%. However, the stock has experienced a downturn of over 25% in the past week.
From a technical perspective, Natco Pharma is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages.
NATCO Pharma Q3 Results Details
NATCO Pharma Ltd reported a 37.75% decrease in consolidated net profit, amounting to Rs 132.4 crore for the December quarter. This decline was attributed to a decrease in formulations exports.
In the same quarter of the previous fiscal year, the company reported a consolidated net profit of Rs 212.7 crore, according to a regulatory filing by NATCO Pharma.
Consolidated revenue from operations for the quarter under review was Rs 474.8 crore, compared to Rs 758.6 crore in the corresponding period of the previous year.
Approval for Generic Everolimus Tablets
Earlier, Natco Pharma received approval from the US health regulator for its generic version of Everolimus tablets for oral suspension. These tablets are indicated for patients with tuberous sclerosis complex.
The approval covers the Abbreviated New Drug Application (ANDA) for Everolimus tablets for oral suspension (TFOS) in strengths of 2mg, 3mg, and 5mg, as stated by Natco Pharma in a regulatory filing.
Sources: https://www.cnbctv18.com/market/natco-pharma-share-price-q3-results-weak-net-profit-revenue-ebitda-margin-extend-losses-stock-reaction-19557938.htm
https://m.economictimes.com/markets/stocks/news/natco-pharma-shares-plunge-16-after-q3-profit-decline-37-yoy-to-rs-132-crore/articleshow/118200686.cms
https://www.indiatvnews.com/business/markets/natco-pharma-stock-tanks-20-per-cent-even-as-markets-trade-higher-quarterly-results-profit-details-2025-02-13-976050